Market Overview

GW Pharmaceutical's Upcoming Epidiolex Data Has Relatively Low Bar for Success

Related GWPH
GW Pharmaceuticals Finds Sellers At A Familiar Level
Mid-Morning Market Update: Markets Gain; Gray Television To Buy Schurz Communications' Television And Radio Stations

On Tuesday, Leerink reiterated an Outperform rating on GW Pharmaceuticals (NASDAQ: GWPH) and $79 price target.

Analyst Joseph Schwartz believes the “bar for success is relatively low” for upcoming Epidiolex data, based on the review of epilepsy trials. Schwartz went on to explain that 20 to 50 percent reduction in seizures versus placebo is generally good enough to approve add-on treatments.

In the second half of 2014, the company will start placebo-controlled proof-of-concept study followed by studies in Dravet and Lennox-Gastaut syndrome in 2015.

Shares closed up 1.5 percent to $66.19 in Tuesday's trading.

Latest Ratings for GWPH

Aug 2015Morgan StanleyInitiates Coverage onOverweight
Apr 2015Leerink SwannMaintainsOutperform
Jul 2014Peel HuntDowngradesBuyHold

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Joseph Schwartz LeerinkAnalyst Color Reiteration Analyst Ratings


Related Articles (GWPH)

View Comments and Join the Discussion!

Get Benzinga's Newsletters